FDA announcements and Relay Therapeutics' official press releases

Relay Therapeutics' RLY-2608 Shows Positive Interim Data, Stock Rises 21.2%

Sep 9, 2024, 11:15 AM

Relay Therapeutics announced on Monday positive interim data for its experimental treatment, RLY-2608, which demonstrates clinically meaningful progression-free survival in patients with HR+/HER2- breast cancer. The early-stage study indicates that the combination treatment significantly extended the time patients lived without their disease worsening. Following the announcement, Relay Therapeutics' stock (RLAY) saw a pre-market increase of 21.2%. Dr. Don Bergstrom, President of R&D at Relay Therapeutics, highlighted the significance of these findings.